Melatonin plus interleukin-2 is more effective as neuroimmunotherapy than melatonin plus somastatin analogs and bromocriptine as polyneuroendocrine therapy in untreatable advanced solid tumor patients

International Journal of Immunotherapy

Volumn 15, Issue 2, 1999, Pages 67-72

  Lissoni, Paolo ^a   Paolorossi, F ^a   Mandala, L ^a   Fumagalli, L ^a   Ardizzoia, A ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; INTERLEUKIN 2; MELATONIN; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE SARCOMA; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR REGRESSION;

EID: 0032732532     PISSN: 02559625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Regelson W., Pierpaoli W. Melatonin: A rediscovered antitumor hormone? Cancer Lett., 5, 379, 1987.
2. Lissoni P., Barni S., Tancini G. et al. A randomised study with subcutaneous low-dose interleukin-2 alone vs interleukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br. J. Cancer, 69, 196, 1994.
3. Lissoni P., Pittalis S., Barni S., et al. Regulation of interleukin-2-interleukin-12 interactions by the pineal gland. Int. J. Thymol., 5, 443, 1997.
4. Reiter R.J., Carneiro R.C., Oh C.S. Melatonin in relation to cellular anti-oxidative defence mechanisms. Horm. Metab. Res., 29, 363, 1997.
5. Molis T.M., Spriggs L., Jupiter Y., Hill S.M. Melatonin modulation of estrogen-regulated proteins, growth factors, and protooncogenes in human breast cancer. J. Pineal Res., 18, 93, 1995.
6. Di Bella L., Rossi M.T., Scalera G. Perspectives in pineal functions. Progr. Brain Res., 52, 475, 1979.
7. Cos S.D., Blask D.E. Melatonin modulates growth factor activity in MCF-7 human breast cancer cells. J. Pineal Res., 17, 25, 1994.
8. Danesi R., Del Tacca M. The effect of the somatostatin analog octreotide on angiogenesis in vitro. Metabolism, 45(Suppl. 1), 49, 1996.
9. Barrett A., Morgan L., Raggatt P.R., Hobbs J.R. Bromocriptine in the treatment of advanced breast cancer. Clin. Oncol., 2, 373, 1976.
10. Stalldecker G.B., Pigni J., Fluentes A.M., Vegh I. Prolactin response to dopamine and valproate administration in breast cancer patients. Biomed. Pharmacother., 43, 301, 1989.
11. Welsch C.W., Nagasa H. Prolactin and murine mammary tumorigenesis: A review. Cancer Res., 37, 951, 1977.
12. Johnson D.E., Ochieng J., Evans S.L. The growth inhibitory properties of a dopamine agonist (SKF 38393) on MCF-7 cells. Anticancer Drugs, 6, 471, 1995.
13. Cussenot O. Growth factors and prostatic tumors. Ann. Endocrinol., 58, 370, 1997.
14. Lissoni P., Laudon M., Barni S., et al. Long-term results of cancer immunotherapy with subcutaneous low-dose interleukin-2 plus melatonin. Int. J. Immunotherapy, XIV, 169, 1998.
15. Lissoni P., Barni S., Crispino S., Tancini G., Fraschini F. Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur. J. Cancer Clin. Oncol., 25, 789, 1989.